Value of FDG PET/CT in Predicting Pathologic Complete
Response After Neoadjuvant Chemotherapy in Locally
Advanced Breast Cancer

Abamor, Evrim; Kucukoz Uzun, Aysun; Tataroglu Ozyukseler, Deniz; Odabas, Hatice; ayhan, murat; Köstek, Osman; çoban kökten, şermin; YILDIRIM, MAHMUT EMRE; turan, nedim

doi:10.14744/ejmi.2022.43076

Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Murat AYHAN, (Sağlık Bilimleri Üniversitesi, Tıbbi Onkoloji Anabilim Dalı Kartal Dr. Lütfi Kırdar Şehir Hastanesi, İstanbul, Türkiye)

Evrim ABAMOR, (Sağlık Bilimleri Üniversitesi Kartal Dr. Lütfi Kırdar Şehir Hastanesi, Nükleer Tıp Anabilim Dalı, İstanbul, Türkiye)

Sermin ÇOBAN KÖKTEN, (Sağlık Bilimleri Üniversitesi Patoloji Anabilim Dalı Kartal Dr. Lütfi Kırdar Şehir Hastanesi, İstanbul, Türkiye)

Hatice ODABAS, (Sağlık Bilimleri Üniversitesi, Tıbbi Onkoloji Anabilim Dalı Kartal Dr. Lütfi Kırdar Şehir Hastanesi, İstanbul, Türkiye)

Deniz TATAROĞLU, (Sağlık Bilimleri Üniversitesi, Tıbbi Onkoloji Anabilim Dalı Kartal Dr. Lütfi Kırdar Şehir Hastanesi, İstanbul, Türkiye)

Osman KÖSTEK, (Edirne Sultan 1. Murat Devlet Hastanesi, Tıbbi Onkoloji Anabilim Dalı, Edirne, Türkiye)

Nedim TURAN, (Sağlık Bilimleri Üniversitesi, Tıbbi Onkoloji Anabilim Dalı Kartal Dr. Lütfi Kırdar Şehir Hastanesi, İstanbul, Türkiye)

Aysun KÜÇÜKÖZ UZUN, (Sağlık Bilimleri Üniversitesi, Tıbbi Onkoloji Anabilim Dalı Kartal Dr. Lütfi Kırdar Şehir Hastanesi, İstanbul, Türkiye)

Mahmut Emre YILDIRIM (Sağlık Bilimleri Üniversitesi, Tıbbi Onkoloji Anabilim Dalı Kartal Dr. Lütfi Kırdar Şehir Hastanesi, İstanbul, Türkiye)

Eurasian Journal of Medical Investigation

3 0

Yıl: 2022 Cilt: 6 Sayı: 2 Sayfa Aralığı: 165 - 175 Metin Dili: İngilizce DOI: 10.14744/ejmi.2022.43076 İndeks Tarihi: 18-07-2022

Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Öz:

Objectives: To investigate the importance of FDG PET/CT in predicting pathologic complete response (pCR) in primary breast lesions and axillary lymph nodes of patients with local, advanced breast cancer who were given neoadjuvant chemotherapy (NAC). Methods: One hundred twenty-one patients who had FDG PET/CT and underwent surgery due to local, advanced breast cancer before and after NAC were involved in the study. SUVmax and SULpeak values before and after NAC were evaluated using FDG PET/CT and post-surgical responses were re-evaluated. Results: Our study included 121 patients in total and 34 patients (28.1%) had a complete response in the breast, and 53 patients (43.8%) had a complete response in axillary lymph nodes. PostSUVmax and PostSULpeak values ≤1.15 and the activity presenting the pCR were controlled and the sensitivity and specificity were found as 61.8% and 61.8%, and 73.3% and 77.0%, respectively, for the breast (p<0.001 and p<0.001). The reduction rate (RR) of SUVmax >88% and the SULpeak (RR) >81% values and the activity presenting the pCR were controlled and the sensitivity and specificity were found as 80.0% and 81.8%, and 80.0% and 60.7%, respectively, for the breast (p<0.001 and p<0.001). Conclusion: The decrease of SUVmax and SULpeak values detected between PET/CT studies before and after NAC were well correlated with the pathologic response. FDG- PET/CT has high sensitivity and specificity in the evaluation of treatment response rates in breast lesions of patients with breast cancer receiving NAC.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik

1. Lee MC, Newman LA. Management of patients with locally advanced breast cancer. Surg Clin North Am 2007;87:379–98, ix.
2. Lee SC, Grant E, Sheth P, Garcia AA, Desai B, Ji L, et al. Accuracy of contrast-enhanced ultrasound compared with magnetic resonance imaging in assessing the tumor response after neoadjuvant chemotherapy for breast cancer. J Ultrasound Med 2017;36:901–11.
3. Man VC, Cheung PS. Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer. Hong Kong Med J 2017;23:251–7.
4. Wahl RL. Positron Emission Tomography (PET): an update on applications in breast cancer. Breast Dis 1998;10:165–75.
5. Kim SJ, Kim SK, Lee ES, Ro J, Kang Sh. Predictive value of [18F] FDG PET for pathological response of breast cancer to neoadjuvant chemotherapy. Ann Oncol 2004;15:1352–7.
6. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785–808.
7. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006;33:254–62.
8. Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 2014;260:608–14;discussion 614–6.
9. Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009;36:1551–7.
10. Baum RP, Przetak C. Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET). Q J Nucl Med 2001;45:257–68.
11. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000;27:861–6.
12. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700–8.
13. Gennari A, Donati S, Salvadori B, Giorgetti A, Salvadori PA, Sorace O, et al. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000;1:156–61; discussion 162–3.
14. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S–50S.
15. Tahari AK, Chien D, Azadi JR, Wahl RL. Optimum lean body formulation for correction of standardized uptake value in PET imaging. J Nucl Med 2014;55:1481–4.
16. O JH, Lodge MA, Wahl RL. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology 2016;280:576–84.
17. Avril S, Muzic RF Jr, Plecha D, Traughber BJ, Vinayak S, Avril N. ¹⁸ F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer. J Nucl Med 2016;57:34S–9S.
18. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995;180:297–306.
19. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986;46:2578–81.
20. Machiavelli MR, Romero AO, Pérez JE, Lacava JA, Domínguez ME, Rodríguez R, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4:125–31.
21. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77:621–6.
22. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019–27.
23. Iakovou I, Giannoula E, Gkantaifi A, Levva S, Frangos S. Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals. European J Hybrid Imaging 2018;2:20.
24. Fowler AM, Mankoff DA, Joe BN. Imaging neoadjuvant therapy response in breast cancer. Radiology 2017;285:358–75.
25. Gil-Rendo A, Martínez-Regueira F, Zornoza G, García-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 2009;96:166–70.
26. Couturier O, Jerusalem G, N'Guyen JM, Hustinx R. Sequential positron emission tomography using [18F] fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 2006;12:6437–43.
27. Groheux D, Majdoub M, Sanna A, de Cremoux P, Hindié E, Giacchetti S, et al. Early metabolic response to neoadjuvant treatment: FDG PET/CT criteria according to breast cancer subtype. Radiology 2015;277:358–71.
28. Groheux D, Mankoff D, Espié M, Hindié E. ¹⁸F-FDG PET/CT in the early prediction of pathological res0ponse in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. Eur J Nucl Med Mol Imaging 2016;43:983–93.
29. Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med 2008;49:1038–46.
30. Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34:1915–24.
31. Im HJ, Kim YK, Kim YI, Lee JJ, Lee WW, Kim SE. Usefulness of combined metabolic-volumetric indices of (18)F-FDG PET/CT for the early prediction of neoadjuvant chemotherapy outcomes in breast cancer. Nucl Med Mol Imaging 2013;47:36– 43.
32. Han S, Choi JY. Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and metaanalysis. Breast Cancer Res 2020;22:119.
33. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 2009;27:535–41.
34. Akimoto E, Kadoya T, Kajitani K, Emi A, Shigematsu H, Ohara M, et al. Role of 18F-PET/CT in predicting prognosis of patients with breast cancer after neoadjuvant chemotherapy. Clin Breast Cancer 2018;18:45–52.
35. Robertson IJ, Hand F, Kell MR. FDG-PET/CT in the staging of local/ regional metastases in breast cancer. Breast 2011;20:491–4.
36. Kitajima K, Miyoshi Y. Present and future role of FDG-PET/CT imaging in the management of breast cancer. Jpn J Radiol 2016;34:167–80.
37. Ahn JH, Son EJ, Kim JA, Youk JH, Kim EK, Kwak JY, et al. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer. Acta Radiol 2010;51:859–65.
38. Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007;18:473–8.
39. Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters MJ, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 2011;29:660–6.
40. Humbert O, Cochet A, Coudert B, Berriolo-Riedinger A, Kanoun S, Brunotte F, et al. Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist 2015;20:94–104.
41. Akdeniz N, Kömek H, Küçüköner M, Kaplan MA, Urakçi Z, Oruç Z, et al. The role of basal 18F-FDG PET/CT maximum standard uptake value and maximum standard uptake change in predicting pathological response in breast cancer patients receiving neoadjuvant chemotherapy. Nucl Med Commun 2021;42:315–24.

APA	ayhan m, Abamor E, çoban kökten ş, Odabas H, Tataroglu Ozyukseler D, Köstek O, turan n, Kucukoz Uzun A, YILDIRIM M (2022). Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. , 165 - 175. 10.14744/ejmi.2022.43076
Chicago	ayhan murat,Abamor Evrim,çoban kökten şermin,Odabas Hatice,Tataroglu Ozyukseler Deniz,Köstek Osman,turan nedim,Kucukoz Uzun Aysun,YILDIRIM MAHMUT EMRE Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. (2022): 165 - 175. 10.14744/ejmi.2022.43076
MLA	ayhan murat,Abamor Evrim,çoban kökten şermin,Odabas Hatice,Tataroglu Ozyukseler Deniz,Köstek Osman,turan nedim,Kucukoz Uzun Aysun,YILDIRIM MAHMUT EMRE Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. , 2022, ss.165 - 175. 10.14744/ejmi.2022.43076
AMA	ayhan m,Abamor E,çoban kökten ş,Odabas H,Tataroglu Ozyukseler D,Köstek O,turan n,Kucukoz Uzun A,YILDIRIM M Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. . 2022; 165 - 175. 10.14744/ejmi.2022.43076
Vancouver	ayhan m,Abamor E,çoban kökten ş,Odabas H,Tataroglu Ozyukseler D,Köstek O,turan n,Kucukoz Uzun A,YILDIRIM M Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. . 2022; 165 - 175. 10.14744/ejmi.2022.43076
IEEE	ayhan m,Abamor E,çoban kökten ş,Odabas H,Tataroglu Ozyukseler D,Köstek O,turan n,Kucukoz Uzun A,YILDIRIM M "Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer." , ss.165 - 175, 2022. 10.14744/ejmi.2022.43076
ISNAD	ayhan, murat vd. "Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer". (2022), 165-175. https://doi.org/10.14744/ejmi.2022.43076

APA	ayhan m, Abamor E, çoban kökten ş, Odabas H, Tataroglu Ozyukseler D, Köstek O, turan n, Kucukoz Uzun A, YILDIRIM M (2022). Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Eurasian Journal of Medical Investigation, 6(2), 165 - 175. 10.14744/ejmi.2022.43076
Chicago	ayhan murat,Abamor Evrim,çoban kökten şermin,Odabas Hatice,Tataroglu Ozyukseler Deniz,Köstek Osman,turan nedim,Kucukoz Uzun Aysun,YILDIRIM MAHMUT EMRE Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Eurasian Journal of Medical Investigation 6, no.2 (2022): 165 - 175. 10.14744/ejmi.2022.43076
MLA	ayhan murat,Abamor Evrim,çoban kökten şermin,Odabas Hatice,Tataroglu Ozyukseler Deniz,Köstek Osman,turan nedim,Kucukoz Uzun Aysun,YILDIRIM MAHMUT EMRE Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Eurasian Journal of Medical Investigation, vol.6, no.2, 2022, ss.165 - 175. 10.14744/ejmi.2022.43076
AMA	ayhan m,Abamor E,çoban kökten ş,Odabas H,Tataroglu Ozyukseler D,Köstek O,turan n,Kucukoz Uzun A,YILDIRIM M Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Eurasian Journal of Medical Investigation. 2022; 6(2): 165 - 175. 10.14744/ejmi.2022.43076
Vancouver	ayhan m,Abamor E,çoban kökten ş,Odabas H,Tataroglu Ozyukseler D,Köstek O,turan n,Kucukoz Uzun A,YILDIRIM M Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Eurasian Journal of Medical Investigation. 2022; 6(2): 165 - 175. 10.14744/ejmi.2022.43076
IEEE	ayhan m,Abamor E,çoban kökten ş,Odabas H,Tataroglu Ozyukseler D,Köstek O,turan n,Kucukoz Uzun A,YILDIRIM M "Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer." Eurasian Journal of Medical Investigation, 6, ss.165 - 175, 2022. 10.14744/ejmi.2022.43076
ISNAD	ayhan, murat vd. "Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer". Eurasian Journal of Medical Investigation 6/2 (2022), 165-175. https://doi.org/10.14744/ejmi.2022.43076